HELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

被引：0

作者：

Adams, David ^{[1
]}

Tournev, Ivailo L. ^{[2
,3
]}

Taylor, Mark S. ^{[4
,5
]}

Coelho, Teresa ^{[6
]}

Plante-Bordeneuve, Violaine ^{[7
]}

Berk, John L. ^{[8
]}

Gonzalez-Duarte, Alejandra ^{[9
]}

Gillmore, Julian D. ^{[10
]}

Low, Soon-Chai ^{[11
]}

Sekijima, Yoshiki ^{[12
]}

Obici, Laura ^{[13
]}

Blakesley, Rick ^{[14
]}

Arum, Seth ^{[14
]}

Shilling, Rebecca ^{[14
]}

Vest, John ^{[14
]}

Polydefkis, Michael ^{[15
]}

机构：

[1] Univ Paris Saclay, CHU Bicetre, APHP, Dept Neurol,INSERM U1195, Paris, France

[2] Med Univ Sofia, Univ Hosp Aleksandrovska, Dept Neurol, Clin Nervous Dis, Sofia, Bulgaria

[3] New Bulgarian Univ, Dept Cognit Sci, Sofia, Bulgaria

[4] Univ Sydney, Westmead Hosp, Dept Clin Immunol & Allergy, Sydney, NSW, Australia

[5] Univ Sydney, Westmead Clin Sch, Sydney, NSW, Australia

[6] Hosp Santo Antonio, Ctr Hosp Porto, Porto, Portugal

[7] CHU Henri Mondor, Assistance Publ Hop Paris, Neurol Amyloid network, Creteil, France

[8] Boston Med Ctr, Boston, MA USA

[9] Inst Nacl Ciencias Medicas Nutr Salvador Zubiran, Madrid, Spain

[10] UCL, Royal Free Hosp, Natl Amyloidosis Ctr, London, England

[11] Univ Malaya, Dept Med, Div Neurol, Kuala Lumpur, Malaysia

[12] Shinshu Univ, Dept Med Neurol Rheumatol, Sch Med, Matsumoto, Nagano, Japan

[13] IRCCS Fdn Policlin San Matteo, Amyloidosis Res & Treatment Ctr, Pavia, Italy

[14] Alnylam Pharm, Cambridge, England

[15] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21218 USA

来源：

NEUROLOGY | 2021年 / 96卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

1234

引用

页数：4

共 50 条

[21] SIMULATED TREATMENT COMPARISON AND MATCHINGADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF EPLONTERSEN AND VUTRISIRAN FOR THE TREATMENT OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
Karam, C.
Gillmore, J. D.
Chen, G.
Jenkins, N. C.
Hale, M. J.
Chen, J.
Viney, N. J.
Schneider, E.
VALUE IN HEALTH, 2023, 26 (12) : S46 - S47
[22] Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy
Mueschen, Lars H.
Koerner, Gudrun
Gingele, Stefan
Haenselmann, Anja
Bavendiek, Udo
Skripuletz, Thomas
MUSCLE & NERVE, 2021, 64 (03) : E11 - E13
[23] A MULTI-METHOD APPROACH TO AN INDIRECT TREATMENT COMPARISON OF EPLONTERSEN AND VUTRISIRAN FOR THE TREATMENT OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
Karam, C.
Gillmore, J. D.
Chen, G.
Jenkins, N. C.
Hale, M. J.
Taylor, G. M.
Chen, J.
Viney, N. J.
Schneider, E.
VALUE IN HEALTH, 2023, 26 (06) : S279 - S279
[24] Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation
Schmidt, Hartmut H.
Wixner, Jonas
Plante-Bordeneuve, Violaine
Munoz-Beamud, Francisco
Llado, Laura
Gillmore, Julian D.
Mazzeo, Anna
Li, Xingyu
Arum, Seth
Jay, Patrick Y.
Adams, David
AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (06) : 1646 - 1657
[25] Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
Daniel P. Judge
Arnt V. Kristen
Martha Grogan
Mathew S. Maurer
Rodney H. Falk
Mazen Hanna
Julian Gillmore
Pushkal Garg
Akshay K. Vaishnaw
Jamie Harrop
Christine Powell
Verena Karsten
Xiaoping Zhang
Marianne T. Sweetser
John Vest
Philip N. Hawkins
Cardiovascular Drugs and Therapy, 2020, 34 : 357 - 370
[26] Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
Judge, Daniel P.
Kristen, Arnt V.
Grogan, Martha
Maurer, Mathew S.
Falk, Rodney H.
Hanna, Mazen
Gillmore, Julian
Garg, Pushkal
Vaishnaw, Akshay K.
Harrop, Jamie
Powell, Christine
Karsten, Verena
Zhang, Xiaoping
Sweetser, Marianne T.
Vest, John
Hawkins, Philip N.
CARDIOVASCULAR DRUGS AND THERAPY, 2020, 34 (03) : 357 - 370
[27] Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy
Grogan, Martha
Hawkins, Philip N.
Kristen, Arnt V.
Berk, John L.
Suhr, Ole B.
Lin, Hollis
Merkel, Madeline
McManus, Anastasia
Powell, Christine
Vest, John
Karsten, Verena
Judge, Daniel P.
JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S9 - S10
[28] LONGTERM TREATMENT EFFECTS OF INOTERSEN ON QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
Brown, Duncan
Karam, Chafic
Yang, Min
Done, Nicolae
Zhu, JingJing
Greatsinger, Ali
Bozas, Ana
Llonch, Montserrat Vera
Signorovitch, James
MUSCLE & NERVE, 2021, 64 : S57 - S57
[29] Long-term Integrated Safety of Patisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Gillmore, Julian
Berk, John
Dispenzieri, Angela
Polydefkis, Michael
Gonzalez-Duarte, Alejandra
Sekijima, Yoshiki
Sweetser, Marianne T.
Arum, Seth
Wang, Jing Jing
White, Matthew T.
Maurer, Mathew
JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S67 - S68
[30] IDENTIFYING MIXED PHENOTYPE: EVALUATING THE PRESENCE OF POLYNEUROPATHY IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY
Grogan, Martha
Hawkins, Philip
Kristen, Arnt
Berk, John
Suhr, Ole B.
Lin, Hollis
Merkel, Madeline
McManus, Anastasia
Powell, Christine
Vest, John
Karsten, Verena
Judge, Daniel
MUSCLE & NERVE, 2020, 62 : S107 - S107

← 1 2 3 4 5 →